机译:现在是将树突状细胞疗法用于1型糖尿病的时候了
Department of Medicine, Columbia Center for Translational Immunology and Naomi Berrie Diabetes Center, Columbia University Medical Center, New York, NY;
Division of Immunogenetics, Department of Pediatrics, John G. Rangos Research Center, Children's Hospital of Pittsburgh, University of Pittsburgh School of Medicine, Pittsburgh, PA;
Division of Immunogenetics, Department of Pediatrics, John G. Rangos Research Center, Children's Hospital of Pittsburgh, University of Pittsburgh School of Medicine, Pittsburgh, PA;
Department of Pathology, Immunology and Laboratory Medicine, University of Florida College of Medicine, Gainesville, FL;
Division of Immunology and Rheumatology, Department of Medicine, Stanford University School of Medicine, Stanford, CA;
机译:传染性耐受作为1型糖尿病的候选疗法:免疫调节特性从人调节性T细胞转移到其他T细胞和促炎性树突状细胞
机译:临床试验十字路口的致耐受性树突状细胞和T调节细胞用于治疗自身免疫性疾病;重视1型糖尿病的治疗
机译:α1-抗胰蛋白酶治疗下调最近接受过诊断的1型糖尿病患者单核细胞和髓样树突状细胞中Toll样受体诱导的IL-1β反应,并可能改善胰岛功能。
机译:用于治疗1型糖尿病的树突状细胞靶向微粒疫苗
机译:I型糖尿病中树突状细胞的发育和分布:通过体内树突状细胞群体的药物治疗操作,克服遗传缺陷并建立耐受性。
机译:现在是将树突状细胞疗法用于1型糖尿病的时候了
机译:是时候将树突细胞疗法带入1型糖尿病